Studying Suboxone Act

Bill: 118-hr-4053
Sponsor: full_name: Rep. Kuster, Ann M. [D-NH-2]
Introduced: 2023-06-13
Policy area: Health
Subjects: Drug trafficking and controlled substances

Government studies and investigations
Latest action: action_date: 2023-06-16
text: Referred to the Subcommittee on Health.

Summaries:
action_date: 2023-06-13
action_desc: Introduced in House
text: <p><strong>Studying Suboxone Act&nbsp;</strong></p><p>This bill requires the Department of Health and Human Services (HHS) and the Drug Enforcement Administration (DEA) to reevaluate the scheduling of buprenorphine-naloxone combination products (e.g., suboxone) under the Controlled Substances Act.&nbsp;These products are used to treat opioid addictions and are currently schedule III controlled substances. (A schedule III controlled substance is a drug, substance, or chemical that has less potential for abuse than a schedule I or II substance; that has a currently accepted medical use; and that has low or moderate risk of dependence if abused.)</p><p>Specifically, the bill requires HHS to review scientific and medical evaluations relating to these products and update its scheduling recommendations accordingly. The DEA must review the recommendations of HHS and make appropriate scheduling changes.&nbsp;</p><!--tinycomments|2.1|data:application/json;base64,eyJtY2UtY29udmVyc2F0aW9uXzg0NDI5MjMyMTcxOTAwNTE5NzY4NyI6eyJ1aWQiOiJtY2UtY29udmVyc2F0aW9uXzg0NDI5MjMyMTcxOTAwNTE5NzY4NyIsImNvbW1lbnRzIjpbeyJ1aWQiOiJtY2UtY29udmVyc2F0aW9uXzg0NDI5MjMyMTcxOTAwNTE5NzY4NyIsImF1dGhvciI6InNzdWJyYW1hbmlhbUBsaWIubG9jLmdvdiIsImF1dGhvck5hbWUiOiJzc3VicmFtYW5pYW1AbGliLmxvYy5nb3YiLCJjb250ZW50IjoiaHR0cHM6Ly93d3cuZGVhZGl2ZXJzaW9uLnVzZG9qLmdvdi9kcnVnX2NoZW1faW5mby9idXByZW5vcnBoaW5lLnBkZiIsImNyZWF0ZWRBdCI6IjIwMjQtMDYtMjFUMjE6MjY6MzcuNjg3WiIsIm1vZGlmaWVkQXQiOiIyMDI0LTA2LTIxVDIxOjI2OjM3LjY4N1oifV19LCJtY2UtY29udmVyc2F0aW9uXzQ1MjM0NjgzODMxNzE5MDA1NjI0NDcwIjp7InVpZCI6Im1jZS1jb252ZXJzYXRpb25fNDUyMzQ2ODM4MzE3MTkwMDU2MjQ0NzAiLCJjb21tZW50cyI6W3sidWlkIjoibWNlLWNvbnZlcnNhdGlvbl80NTIzNDY4MzgzMTcxOTAwNTYyNDQ3MCIsImF1dGhvciI6InNzdWJyYW1hbmlhbUBsaWIubG9jLmdvdiIsImF1dGhvck5hbWUiOiJzc3VicmFtYW5pYW1AbGliLmxvYy5nb3YiLCJjb250ZW50IjoiaHR0cHM6Ly93d3cuY29uZ3Jlc3MuZ292L2JpbGwvMTE4dGgtY29uZ3Jlc3MvaG91c2UtYmlsbC82MTA/cT0lN0IlMjJzZWFyY2glMjIlM0ElMjIlNUMlMjJzY2hlZHVsZStpaWklNUMlMjIlMjIlN0Qmcz0zJnI9MSIsImNyZWF0ZWRBdCI6IjIwMjQtMDYtMjFUMjE6MzM6NDQuNDcwWiIsIm1vZGlmaWVkQXQiOiIyMDI0LTA2LTIxVDIxOjMzOjQ0LjQ3MFoifV19fQ==-->

tv_txt: I 118th CONGRESS 1st Session H. R. 4053 IN THE HOUSE OF REPRESENTATIVES June 13, 2023 Ms. Kuster (for herself and Mr. Carter of Georgia ) introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committee on the Judiciary , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To provide for the review of the scheduling under the Controlled Substances Act of buprenorphine-naloxone combination products, and for other purposes.

1. Short title This Act may be cited as the Studying Suboxone Act . 2. Reviewing the scheduling of buprenorphine-naloxone combination products (a) Secretary of HHS The Secretary of Health and Human Services shall— (1) review and, as appropriate, update the scientific and medical evaluation conducted under section 201(b) of the Controlled Substance Act ( 21 U.S.C. 811(b) ) with respect to buprenorphine-naloxone combination products; and (2) update, as necessary, the Secretary’s scheduling recommendation under such section with respect to such products. (b) Attorney General The Attorney General shall— (1) review the recommendations provided by the Secretary under subsection (a), and all other relevant data with respect to the scheduling of buprenorphine-naloxone combination products; (2) consider the factors listed in subsection (c) of section 201 of the Controlled Substance Act ( 21 U.S.C. 811 ) with respect to such products; and (3) consistent with such section 201, make such scheduling changes with respect to such products as the Secretary may determine appropriate.